首页> 外文期刊>Experimental and therapeutic medicine >Construction and verification of the targeted uPA-shRNA lentiviral vector and evaluation of the transfection and silencing rate
【24h】

Construction and verification of the targeted uPA-shRNA lentiviral vector and evaluation of the transfection and silencing rate

机译:靶向uPA-shRNA慢病毒载体的构建和验证以及转染和沉默率的评估

获取原文
获取原文并翻译 | 示例
           

摘要

Urokinase-type plasminogen activator (uPA) receptors, which are released by the synovial tissue, are responsible for the activation of cartilage-breakdown proteases and play critical roles in cartilage degradation during the progression of osteoarthritis (OA). RNA interference (RNAi) technology has emerged as a potent tool to generate cellular knockdown phenotypes of a desired gene. The aims of the present study were to investigate the effect of siRNA specific to the uPA gene on chondrocytes and to investigate the possible mechanisms of OA. Firstly, four types of small hairpin RNA (shRNA) sequence (P1, P2, P3 and P4) were obtained from the targeted uPA gene of the New Zealand rabbit, based on siRNA theory. The sequences were designed, constructed and subjected to restriction enzyme digestion, transformation, polymerase chain reaction (PCR) identification, positive clone sequencing and lentivirus packaging. Secondly, primary culturing cartilage cells from the New Zealand rabbit were transfected with P1, P2, P3 or P4 to observe the transfection rate under a fluorescence microscope. The mRNA expression levels of uPA were analyzed in cartilage cells using quantitative PCR, while protein expression levels were analyzed in the cartilage cells using western blot technology. Four types of uPA-shRNA lentiviral vectors were constructed successfully, which were all able to be transfected into the primary culturing cartilage cells. The transfection rate was as high as 85% when the multiplicity of infection was 100, which demonstrated that P1, P2, P3 and P4 were all capable of inhibiting the mRNA and protein expression of uPA in cartilage cells. In addition, among the four sequences, the P2 sequence exhibited the highest silencing rate of 70%. Statistical significance (P<0.05) was observed when analyzing the silencing rate of P2 compared to the other three groups. The most efficient targeted uPA-shRNA sequence was identified following screening. The results strongly verified that siRNA lentiviral vectors can be transfected into cartilage cells to further inhibit the expression of the uPA gene efficiently and steadily. Thus, the results provide the foundation for further research on the role of uPA in the pathogenesis of OA.
机译:滑膜组织释放的尿激酶型纤溶酶原激活剂(uPA)受体负责激活软骨分解蛋白酶,并在骨关节炎(OA)的发展过程中在软骨降解中起关键作用。 RNA干扰(RNAi)技术已经成为一种产生所需基因的细胞敲除表型的有效工具。本研究的目的是研究针对uPA基因的siRNA对软骨细胞的影响,并探讨OA的可能机制。首先,基于siRNA理论,从新西兰兔的靶向uPA基因中获得了四种类型的小发夹RNA(shRNA)序列(P1,P2,P3和P4)。设计,构建序列并进行限制酶消化,转化,聚合酶链反应(PCR)鉴定,阳性克隆测序和慢病毒包装。其次,将新西兰兔的原代培养软骨细胞用P1,P2,P3或P4转染,在荧光显微镜下观察转染率。使用定量PCR分析了软骨细胞中uPA的mRNA表达水平,而使用蛋白质印迹技术分析了软骨细胞中的蛋白表达水平。成功构建了四种类型的uPA-shRNA慢病毒载体,它们都可以被转染到原代培养的软骨细胞中。当感染复数为100时,转染率高达85%,表明P1,P2,P3和P4均能够抑制软骨细胞中uPA的mRNA和蛋白表达。另外,在这四个序列中,P2序列表现出70%的最高沉默率。与其他三组相比,分析P2的沉默率时有统计学意义(P <0.05)。筛选后鉴定出最有效的靶向uPA-shRNA序列。结果强烈证实了siRNA慢病毒载体可以被转染到软骨细胞中,以进一步有效和稳定地抑制uPA基因的表达。因此,结果为进一步研究uPA在OA发病机制中的作用提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号